Intranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces long-term protective immunity against respiratory syncytial virus

References

• Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749-59; PMID:15858184; https://doi.org/10.1056/NEJMoa043951
   PubMed Web of Science ®Google Scholar
• Group TI-RS. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics 1998; 102:531-7; https://doi.org/10.1542/peds.102.3.531
   Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422-34; PMID:4305198; https://doi.org/10.1093/oxfordjournals.aje.a120955
   PubMed Web of Science ®Google Scholar
• Collins PL, Graham BS. Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis. J Virol 2008; 82:2040-55; PMID:17928346; https://doi.org/10.1128/JVI.01625-07
   PubMed Web of Science ®Google Scholar
• Vaux-Peretz F, Chapsal JM, Meignier B. Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice. Vaccine 1992; 10:113-8; PMID:1539464; https://doi.org/10.1016/0264-410X(92)90027-H
   PubMed Web of Science ®Google Scholar
• Garlapati S, Garg R, Brownlie R, Latimer L, Simko E, Hancock REW, Babiuk LA, Gerdts V, Potter A, van Drunen Littel-van den Hurk S. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles. Vaccine 2012; 30:5206-14; PMID:22713718; https://doi.org/10.1016/j.vaccine.2012.06.011
   PubMed Web of Science ®Google Scholar
• Sivori S, Falco M, Chiesa MD, Carlomagno S, Vitale M, Moretta L, Moretta A. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: Induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci U S A 2004; 101:10116-21; PMID:15218108; https://doi.org/10.1073/pnas.0403744101
   PubMed Web of Science ®Google Scholar
• Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, Salazar AM, Colonna M, Steinman RM. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 2009; 206:1589-602; PMID:19564349; https://doi.org/10.1084/jem.20090247
   PubMed Web of Science ®Google Scholar
• Yeung A, Gellatly S, Hancock R. Multifunctional cationic host defence peptides and their clinical applications. Cell Mol Life Sci 2011; 68:1-16.
   PubMed Web of Science ®Google Scholar
• Andrianov AK, DeCollibus DP, Gillis HA, Kha HH, Marin A, Prausnitz MR, Babiuk LA, Townsend H, Mutwiri G. Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. Proc Natl Acad Sci U S A 2009; 106:18936-41; PMID:19864632; https://doi.org/10.1073/pnas.0908842106
   PubMed Web of Science ®Google Scholar
• Kovacs-Nolan J, Latimer L, Landi A, Jenssen H, Hancock RE, Babiuk LA, van Drunen Littel-van den Hurk S. The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. Vaccine 2009; 27:2055-64; PMID:19428830; https://doi.org/10.1016/j.vaccine.2009.01.118
   PubMed Web of Science ®Google Scholar
• Garg R, Latimer L, Gerdts V, Potter A, van Drunen Littel-van den Hurk S. Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity. J Gen Virol 2014; 95:1043-54; PMID:24572813; https://doi.org/10.1099/vir.0.062570-0
   PubMed Web of Science ®Google Scholar
• Garg R, Latimer L, Gerdts V, Potter A, van Drunen Littel-van den Hurk S. The respiratory syncytial virus fusion protein formulated with a novel combination adjuvant induces balanced immune responses in lambs with maternal antibodies. Vaccine 2015; 33:1338-44; PMID:25637860; https://doi.org/10.1016/j.vaccine.2015.01.041
   PubMed Web of Science ®Google Scholar
• Johnstone C, de Leon P, Medina F, Melero JA, Garcia-Barreno B, Del Val M. Shifting immunodominance pattern of two cytotoxic T-lymphocyte epitopes in the F glycoprotein of the Long strain of respiratory syncytial virus. J Gen Virol 2004; 85:3229-38; PMID:15483236; https://doi.org/10.1099/vir.0.80219-0
   PubMed Web of Science ®Google Scholar
• Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011; 239:149-66; PMID:21198670; https://doi.org/10.1111/j.1600-065X.2010.00972.x
   PubMed Web of Science ®Google Scholar
• Power UF. Respiratory syncytial virus (RSV) vaccines–two steps back for one leap forward. J Clin Virol 2008; 41:38-44; PMID:18340669; https://doi.org/10.1016/j.jcv.2007.10.024
   PubMed Web of Science ®Google Scholar
• Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001; 344:1917-28; PMID:11419430; https://doi.org/10.1056/NEJM200106213442507
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011; 12:509-17; PMID:21739679; https://doi.org/10.1038/ni.2039
   PubMed Web of Science ®Google Scholar
• Garg R, Latimer L, Simko E, Gerdts V, Potter A, van den Hurk S. Induction of mucosal immunity and protection by intranasal immunization with a respiratory syncytial virus subunit vaccine formulation. J Gen Virol 2014; 95:301-6; PMID:24136365; https://doi.org/10.1099/vir.0.058461-0
   PubMed Web of Science ®Google Scholar
• Blanco JC, Boukhvalova MS, Pletneva LM, Shirey KA, Vogel SN. A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology. Vaccine 2014; 32:1495-500; PMID:24252693; https://doi.org/10.1016/j.vaccine.2013.11.032
   PubMed Web of Science ®Google Scholar
• Lambert SL, Aslam S, Stillman E, MacPhail M, Nelson C, Ro B, Sweetwood R, Lei YM, Woo JC, Tang RS. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models. PLoS One 2015; 10:e0119509; PMID:25793508; https://doi.org/10.1371/journal.pone.0119509
   PubMed Web of Science ®Google Scholar
• Kim TS, Hufford MM, Sun J, Fu YX, Braciale TJ. Antigen persistence and the control of local T cell memory by migrant respiratory dendritic cells after acute virus infection. J Exp Med 2010; 207:1161-72; PMID:20513748; https://doi.org/10.1084/jem.20092017
   PubMed Web of Science ®Google Scholar
• Watt PJ, Robinson BS, Pringle CR, Tyrrell DA. Determinants of susceptibility to challenge and the antibody response of adult volunteers given experimental respiratory syncytial virus vaccines. Vaccine 1990; 8:231-6; PMID:2363300; https://doi.org/10.1016/0264-410X(90)90051-M
   PubMed Web of Science ®Google Scholar
• Schmidt MR, McGinnes LW, Kenward SA, Willems KN, Woodland RT, Morrison TG. Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains. J Virol 2012; 86:11654-62; PMID:22896618; https://doi.org/10.1128/JVI.01510-12
   PubMed Web of Science ®Google Scholar
• Garg R, Theaker M, Martinez EC, van Drunen Littel-van den Hurk S. A single intranasal immunization with a subunit vaccine formulation induces higher mucosal IgA production than live respiratory syncytial virus. Virology 2016; 499:288-97; PMID:27721128; https://doi.org/10.1016/j.virol.2016.09.023
   PubMed Web of Science ®Google Scholar
• Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009; 15:34-41; PMID:19079256; https://doi.org/10.1038/nm.1894
   PubMed Web of Science ®Google Scholar
• Xu W, Santini PA, Matthews AJ, Chiu A, Plebani A, He B, Chen K, Cerutti A. Viral double-stranded RNA triggers Ig class switching by activating upper respiratory mucosa B cells through an innate TLR3 pathway involving BAFF. J Immunol 2008; 181:276-87; https://doi.org/10.4049/jimmunol.181.1.276
   PubMed Web of Science ®Google Scholar
• Stowell NC, Seideman J, Raymond HA, Smalley KA, Lamb RJ, Egenolf DD, Bugelski PJ, Murray LA, Marsters PA, Bunting RA, et al. Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice. Resp Res 2009; 10:43; https://doi.org/10.1186/1465-9921-10-43
   PubMed Web of Science ®Google Scholar
• Boukhvalova MS, Sotomayor TB, Point RC, Pletneva LM, Prince GA, Blanco JC. Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model. J Interferon Cytokine Res 2010; 30:229-42; PMID:20038196; https://doi.org/10.1089/jir.2009.0025
   PubMed Web of Science ®Google Scholar
• Aeffner F, Traylor ZP, Yu EN, Davis IC. Double-stranded RNA induces similar pulmonary dysfunction to respiratory syncytial virus in BALB/c mice. Am J Physiol Lung Cell Mol Physiol 2011; 301:L99-L109; PMID:21478252; https://doi.org/10.1152/ajplung.00398.2010
   PubMed Web of Science ®Google Scholar
• Bowdish DME, Davidson DJ, Scott MG, Hancock REW. Immunomodulatory Activities of Small Host Defense Peptides. Antimicrob Agents Chemother 2005; 49:1727-32; PMID:15855488; https://doi.org/10.1128/AAC.49.5.1727-1732.2005
   PubMed Web of Science ®Google Scholar
• Hancock REW, Sahl H-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotech 2006; 24:1551-7; https://doi.org/10.1038/nbt1267
   PubMed Web of Science ®Google Scholar
• Andrianov AK, Marin A, Roberts BE. Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. Biomacromolecules 2005; 6:1375-9; PMID:15877355; https://doi.org/10.1021/bm049329t
   PubMed Web of Science ®Google Scholar
• Lee FE, Walsh EE, Falsey AR, Lumb ME, Okam NV, Liu N, Divekar AA, Hall CB, Mosmann TR. Human infant respiratory syncytial virus (RSV)-specific type 1 and 2 cytokine responses ex vivo during primary RSV infection. J Infect Dis 2007; 195:1779-88; PMID:17492594; https://doi.org/10.1086/518249
   PubMed Web of Science ®Google Scholar
• Kumar M, Behera AK, Matsuse H, Lockey RF, Mohapatra SS. Intranasal IFN-gamma gene transfer protects BALB/c mice against respiratory syncytial virus infection. Vaccine 1999; 18:558-67; PMID:10519947; https://doi.org/10.1016/S0264-410X(99)00185-1
   PubMed Web of Science ®Google Scholar
• Mapletoft JW, Oumouna M, Kovacs-Nolan J, Latimer L, Mutwiri G, Babiuk LA, van Drunen Littel-van den Hurk S. Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. J Gen Virol 2008; 89:250-60; PMID:18089749; https://doi.org/10.1099/vir.0.83300-0
   PubMed Web of Science ®Google Scholar